Hutchmed (China) Secures Priority Review for Liver Cancer Drug Fanregratinib in China

MT Newswires · 2d ago
04:48 AM EST, 12/29/2025 (MT Newswires) -- Biopharmaceutical company Hutchmed (China) (HCM.L) said Monday the China National Medical Products Administration accepted its new drug application and granted priority review for liver cancer drug fanregratinib. Fanregratinib is indicated for patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 fusion/rearrangement, with a history of systemic therapy. The application is supported by a Phase II study in China that met its primary endpoint of objective response rate.